New hope for hard-to-treat cancers: targeted combo therapy enters trials
NCT ID NCT07259590
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug (GFH375) combined with either cetuximab or chemotherapy in people with advanced solid tumors that have a specific KRAS G12D mutation. The goal is to see if the combination is safe and can shrink tumors. About 126 adults who have not responded to standard treatments will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Cancer Hospital
RECRUITINGBeijing, Beijing Municipality, China
-
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
NOT_YET_RECRUITINGGuangzhou, Guangdong, China
-
The First Affiliated Hospital of Zhengzhou University
NOT_YET_RECRUITINGZhengzhou, Henan, China
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
NOT_YET_RECRUITINGWuhan, Hubei, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can your own immune cells beat advanced cancer?
- Can a four-pronged attack shrink liver tumors enough for surgery?
- Can a Two-Pronged antibody boost chemo against Hard-to-Treat colorectal cancer?
- New drug cocktail aims to shrink Hard-to-Treat colorectal tumors
- New drug combo aims to boost Chemotherapy's punch against pancreatic cancer
- Blood test may let cancer patients take safe breaks from immunotherapy